Brazil Veterinary Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Medicated Feed Additives), By Animal Type, By Route Of Administration, By Distribution, And Segment Forecasts, 2025 - 2030

Brazil Veterinary Medicine Market Trends

The Brazil veterinary medicine market size was valued at USD 2.65 billion in 2024 and is expected to expand at a CAGR of 7.9% from 2025 to 2030. This growth is driven by the increasing prevalence of animal diseases, rising demand for animal protein, and advancements in veterinary pharmaceuticals. The expanding livestock population and growing pet ownership in urban areas further contribute to market expansion. In addition, regulatory efforts to streamline veterinary drug approvals and strengthen animal health programs support the adoption of vaccines, antimicrobials, and biologics. The increased focus on disease prevention and treatment and increasing awareness of animal welfare is fueling demand for veterinary healthcare products and services across the country.

The increasing focus on research and development in veterinary medicine is expected to drive market growth by improving disease prevention and treatment options for livestock and companion animals. Investments in innovative therapeutics, vaccines, diagnostic solutions, and strategic partnerships are further contributing to market expansion. For instance, in October 2024, Amlan International partnered with VetPro to enhance innovation in animal health across Northern Brazil. This strategic alliance aims to expand access to advanced feed additives that support animal productivity and disease resistance. In addition, collaborations between veterinary institutions and pharmaceutical companies encourage the introduction of novel drugs and precision medicine approaches, ensuring improved disease management and preventive care in Brazil's veterinary sector.

The expansion of veterinary healthcare infrastructure, including the establishment of new animal clinics and specialized care centers, is further strengthening the market. Increased accessibility to veterinary services and advancements in diagnostic technologies enable early disease detection and effective treatment. Furthermore, the growing emphasis on sustainable livestock management and responsible antimicrobial use is shaping industry trends, encouraging the adoption of innovative and eco-friendly veterinary solutions in the Brazil veterinary medicine market.

Evolution of Veterinary Medicine in Brazil

• Early Development (Pre-1990s)

  • Veterinary medicine in Brazil was primarily focused on livestock health, driven by the country's large agricultural and meat-export economy.

  • Major diseases like foot-and-mouth disease (FMD) and bovine brucellosis were the focus of early state-run vaccination campaigns.

• Growth Phase (1990s-2010s)

  • Rapid growth in companion animal ownership, urbanization, and rising income levels led to increased demand for pet care and preventive treatments.

  • Private veterinary clinics proliferated, and multinational pharmaceutical companies began expanding their operations in Brazil.

  • The introduction of broad-spectrum antiparasitic drugs (e.g., ivermectin-based products) and vaccines for pets and poultry became widespread.

• Modernization and Innovation (2010s-2020s)

  • Emergence of advanced diagnostics, telemedicine, and specialty care (oncology, cardiology) in veterinary practices.

  • Increased R&D investments from major players like Zoetis, MSD Saúde Animal, Boehringer Ingelheim, and Ceva.

  • Shift toward combination therapies, nutraceuticals, and personalized pet medicine.

The Brazilian veterinary medicine market has evolved from livestock-centric to a diverse, companion-animal-inclusive sector. Regulatory modernization by MAPA and Anvisa is enabling faster approvals, promoting biosimilars, and addressing global issues like AMR. Brazil increasingly aligns with global veterinary standards, fostering innovation and market growth.

Market Concentration & Characteristics

The industry is experiencing a high degree of innovation, driven by advancements in vaccine development, precision medicine, and AI-powered diagnostics. Companies are introducing biotechnology-based solutions, such as plant-derived therapeutics and microbiome-focused treatments, to enhance animal health. The integration of digital health platforms and smart monitoring tools is also improving disease prevention, treatment precision, and overall veterinary care efficiency.

The level of merger and acquisition activities in the market is moderate, with companies strategically acquiring or merging with others to expand their product portfolios, enhance their market presence, and gain competitive advantages. For instance, in September 2022, Mitsui & Co. acquired a 29.44% stake in Brazil's fourth-largest animal health company, Ouro Fino Saúde Animal, which serves both livestock and companion animal markets in Brazil and Latin America. This investment aligns with Mitsui's focus on animal health amid Brazil's rapidly growing market, driven by high demand for livestock and a rising number of companion animals.

Regulation in the Brazilian industry has a moderate effect, ensuring the safety, efficacy, and quality of veterinary pharmaceuticals and biologics. The Ministry of Agriculture, Livestock, and Food Supply (MAPA) oversees the approval and monitoring of veterinary medicines, vaccines, and animal health products. For example, MAPA's regulations on antimicrobial use in livestock aim to curb antimicrobial resistance while maintaining effective treatment options for animal diseases. These regulatory measures help standardize veterinary practices, ensuring compliance and product reliability across the market.

The industry faces a low to moderate threat from product substitutes, as traditional treatments and preventive care methods remain alternatives to advanced veterinary medicines. Herbal and homeopathic remedies are sometimes used as substitutes, particularly in rural areas, but they often lack the proven efficacy of pharmaceutical treatments. In addition, improved animal husbandry practices and nutritional supplements serve as preventive alternatives, though they do not fully replace the need for veterinary medicines in disease management and treatment.

The industry has a moderate to high end-user concentration, with veterinary hospitals, clinics, and livestock farms playing a significant role in product adoption. Specialized animal hospitals and urban veterinary clinics drive demand for advanced treatments, whereas independent veterinary practices and rural livestock farms also contribute to market growth. Academic institutions and research centers further support the sector by advancing studies in veterinary pharmaceuticals and biologics. This varied end-user landscape reflects a balanced market, with both large-scale facilities and smaller practices influencing demand.

Product Insights

Pharmaceuticals dominated the Brazil veterinary medicine market, accounting for a share of 67.58% in 2024. This can be attributed to the increasing prevalence of food-borne diseases, brucellosis, and zoonotic diseases that are potentially hazardous to animals, thus leading to clinical urgency for the use of potent pharmaceuticals and targeted medicines. In addition, a significant rise in the incidence of animal bites increases the risk of disease and microbe transmission, further propelling the demand for pharmaceuticals.

Biologics are expected to grow at the highest CAGR of 8.8% over the forecast period in the Brazil veterinary medicine market. The increasing adoption of biologics, such as vaccines, monoclonal antibodies, and immunotherapies, is driven by their disease prevention and treatment effectiveness. The rising focus on sustainable livestock management and the growing demand for advanced therapeutics for companion animals further accelerate this segment's expansion. A recent development in this segment is the approval and commercialization of a new subunit vaccine for avian influenza. For instance, in 2023, the Brazilian Ministry of Agriculture, Livestock, and Supply (MAPA) approved a recombinant protein-based subunit vaccine for poultry designed to prevent avian influenza without causing the disease. This vaccine is expected to significantly reduce avian influenza outbreaks, which have previously caused substantial economic losses in the poultry industry.

Animal Type Insights

Production animals dominated the market in 2024, driven by the growing demand for animal protein and the expansion of the livestock sector. The need for veterinary medicines remains strong to ensure herd health and productivity. The increasing prevalence of infectious diseases among cattle, poultry, and swine has led to a higher adoption of vaccines, antibiotics, and antiparasitics. In addition, government initiatives to improve food safety standards and disease control programs further support market growth. Advancements in veterinary pharmaceuticals and biologics are enhancing disease management, making production animal health a key focus area in the industry.

Companion Animals are expected to grow at the fastest CAGR over the forecast period. The rising pet ownership rates and increasing awareness of animal health and wellness are driving this segment’s expansion. The demand for advanced veterinary medicines, including vaccines, therapeutics, and preventive care products, is growing as pet owners seek better healthcare solutions for their animals. In addition, innovations in companion animal diagnostics and treatments, along with regulatory support for veterinary pharmaceuticals, further contribute to market growth. For example, a 2023 survey conducted by the Brazilian Institute of Geography and Statistics (IBGE) found that 40% of households in Brazil own at least one pet, and there are over 149 million pets in the country. The increasing humanization of pets and higher spending on veterinary care position the Companion Animals segment as a key driver in the Brazil veterinary medicine market.

Route Of Administration Insights

The injectable segment dominated the market in 2024 in terms of revenue share. This segment comprises drugs administered via intravenous, intramuscular, and subcutaneous routes. The widespread use of injectable medicines, their higher cost than oral alternatives, and their rapid onset of action contribute to their dominance. Brazil, the world's second-largest beef producer and the largest chicken exporter, relies heavily on injectable vaccines to manage diseases such as Foot-and-Mouth Disease (FMD) and Bovine Respiratory Disease in cattle and poultry. In 2023, nearly 200 million doses of FMD vaccines were administered, reflecting a growing focus on disease prevention in the livestock industry. In addition, the rise in bacterial infections, such as brucellosis and tuberculosis, has led to a 15% increase in the use of injectable antibiotics in cattle.

The other routes segment, which includes intranasal delivery, controlled-release implants, and transdermal patches, is expected to grow the most over the forecast period, registering the highest CAGR. The increasing adoption of alternative drug delivery methods in veterinary medicine is driven by the need for improved patient compliance, sustained drug release, and reduced stress during administration. These methods provide targeted and prolonged therapeutic effects, particularly beneficial for chronic conditions and long-term treatments. In addition, another survey of swine highlighted the potential of novel intranasal formulations to effectively address respiratory infections without the need for injections, offering a more efficient solution for mass vaccination and treatment. These advancements in nasal drug delivery are helping to streamline health management in Brazil's vast livestock industry, which includes over 225 million cattle, large poultry populations, and a significant number of swine.

Distribution Channel Insights

Veterinary hospitals and clinics dominated the market, accounting for the largest share in 2024, driven by accessibility, affordability, and the availability of advanced veterinary treatments. This segment is expected to grow consistently as chronic diseases, including diabetes, arthritis, and heart disease, continue to rise in companion animals. According to the Instituto Pet Brasil, Brazil had over 149 million pets in 2023, including dog and cat populations exceeding 84 million, contributing to the increased demand for veterinary care in hospitals and clinics. The growing adoption of companion pets and the subsequent rise in hospital visits, especially for treatment or readmission, have resulted in higher demand for veterinary pharmaceuticals.

The e-commerce segment is expected to grow at the highest CAGR over the forecast period due to the increasing preference for online platforms for purchasing veterinary medicines. The convenience of home delivery, competitive pricing, and a wide range of product availability contribute to the rising adoption of e-commerce in the veterinary sector. In addition, advancements in digital payment systems, subscription-based pet care services, and improved logistics are further driving segment growth. With pet owners seeking accessible and cost-effective solutions for animal healthcare, online platforms continue to expand their market presence.

Country Insights

The Brazil veterinary medicine industry is expanding with the growing demand for healthcare solutions for companion and livestock animals. The increasing pet ownership rate and rising awareness of animal health drive the demand for advanced veterinary pharmaceuticals and vaccines. In addition, livestock farmers seek effective disease management solutions to ensure productivity and animal welfare. In March 2025, the Brazilian Government announced that a Japanese delegation would visit Brazil to inspect its slaughterhouses—a crucial step toward opening the Japanese market to Brazilian beef and expanding pork exports. This initiative underscores Brazil's commitment to enhancing animal health standards and aligns with international trade regulations, further propelling the veterinary medicine market. With ongoing innovations and regulatory support, the veterinary medicine sector in Brazil continues to evolve, addressing the healthcare needs of a diverse animal population.

Key Brazil Veterinary Medicine Company Insights

Major market players engage in various strategies, such as distribution agreements, mergers and acquisitions, and expansions. Most crucially, they exhibit a high degree of innovation in product research and development to improve their market penetration.

Recent Developments

• In June 2024, Elanco Animal Health secured initial approval in Brazil for Zenrelia, an innovative pet health product, with plans to launch in Q4 2024. This approval, granted by Brazil's Ministry of Agriculture, Livestock and Food Supply, aligns with Elanco's strategy to expand in the Brazilian animal health market, where Zenrelia's effectiveness and convenience are expected to meet significant demand.

• In October 2024, Amlan International partnered with VetPro to distribute its mineral-based feed additives, Calibrin-Z and Varium, in Northern Brazil. This alliance aims to strengthen Amlan's market presence in Brazil's expanding animal nutrition sector by leveraging VetPro's regional expertise to promote innovative feed solutions that enhance livestock health and productivity.

• In July 2024, Biogénesis Bagó opened a new vaccine production plant in Campo Largo, Brazil, with a $30 million investment, making it the largest veterinary vaccine producer in Latin America. The facility will produce over 10 million doses annually for pets and livestock, strengthening Biogénesis Bagó's presence in Brazil’s animal health market and expanding its reach across Latin America. 

• In June 2023, Zoetis introduced Protivity, a vaccine designed to protect beef and dairy calves against respiratory disease caused by Mycoplasma bovis. The vaccine is intended for calves one week of age or older, helping to reduce the impact of respiratory infections that affect herd health and productivity. This development supports cattle producers by improving disease prevention efforts and strengthening animal welfare standards.

Brazil Veterinary Medicine Market Report Scope

Brazil Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Brazil veterinary medicine market report on the basis of product, animal type, route of administration, and distribution channel.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Biologics

    • Vaccines

      • Modified/ Attenuated Live

      • Inactivated (Killed)

      • Other Vaccines (subunit and DNA vaccines)

    • Other Biologics (monoclonal antibodies and regenerative medicine)

  • Pharmaceuticals

    • Parasiticides

    • Anti-infectives

    • Anti-inflammatory

    • Analgesics

    • Others (cardiology, neurology, and hormone/fertility pharmaceuticals)

  • Medicated Feed Additives

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Production Animals

    • Poultry

    • Pigs

    • Cattle

    • Sheep & Goats

    • Others (aquaculture/fish, mules, camel, etc.)

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others (small mammals, birds, rabbits, reptiles, etc.)

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

  • Topical

  • Other Routes (intranasal, controlled-release implants, etc.)

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals & Clinics

  • E-commerce

  • Offline Retail Stores

  • Others